目的 观察清咳平喘颗粒治疗新型冠状病毒感染（痰热郁肺证）患者的临床疗效及安全性。方法 选取2022年3月—2022年6月在上海市公共卫生临床中心新冠病房住院的新型冠状病毒感染（痰热郁肺证）患者60例，根据治疗药物不同分为对照组和治疗组，每组各30例。对照组给予常规治疗，治疗组患者在常规治疗基础上加用清咳平喘颗粒，10 g/次，3次/d。观察两组患者治疗前后中医证候疗效、炎症指标及不良反应。结果 治疗后，治疗组总有效率（86.7%）明显高于对照组（66.7%）（P＜0.05）。治疗后，两组患者日间咳嗽评分和夜间咳嗽评分均低于治疗前（P＜0.05），且治疗组治疗后日间咳嗽评分和夜间咳嗽评分均低于对照组（P＜0.05）。两组患者治疗前后外周血白细胞、降钙素原水平比较差异无统计学意义。治疗后，两组C反应蛋白（CRP）水平较治疗前显著降低（P＜0.05），且治疗后治疗组CRP水平低于对照组（P＜0.05）。两组不良反应发生率比较差异无统计学意义。结论 清咳平喘颗粒治疗轻型、普通型新型冠状病毒感染患者（痰热郁肺证）具有较好的临床疗效，可缓解患者临床症状，安全性较好。

Objective To observe the clinical efficacy and safety of Qingke Pingchuan Granules in treatment of light and common type of novel coronavirus infection (phlegm heat stagnating lung syndrome). Methods Sixty patients with novel coronavirus infection (phlegm heat stagnating lung syndrome) hospitalized in the Novel Coronavirus Unit of Shanghai Public Health Clinical Center from March 2022 to June 2022 were selected and divided into control group and treatment group according to different therapeutic drugs, with 30 cases in each group. Patients in the control group were given conventional treatment. Patients in the treatment group were po administered with Qingke Pingchuan Granules on the basis of conventional treatment, 10 g/time, 3 times daily. The efficacy of TCM syndromes, inflammatory indexes and adverse reactions were observed before and after treatment. Results After treatment, the total effective rate in the treatment group (86.7%) was significantly higher than that in the control group (66.7%) (P < 0.05). After treatment, daytime and nighttime cough scores in 2 groups were lower than before treatment (P < 0.05), and daytime and nighttime cough scores in the treatment group were lower than those in the control group (P < 0.05). There was no significant difference in the levels of peripheral blood leukocytes and procalcitonin between the two groups before and after treatment. After treatment, the level of C-reactive protein (CRP) in the two groups was significantly lower than that before treatment (P < 0.05), and the CRP level in the treatment group was lower than that in the control group (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups. Conclusion Qingke Pingchuan Granules has good clinical efficacy in treatment of light and common type of novel coronavirus infection (phlegm heat stagnating lung syndrome), and can relieve the clinical symptoms of patients, which has good safety.

R974

上海市卫生健康委员会面上项目（202040332）；上海市金山区医药卫生科技创新资金项目（2022-WS-39）